The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert following the identification of more than 100 substandard medications by India’s Central Drugs Standard Control Organization (CDSCO).
The alert comes after CDSCO flagged several pharmaceutical products as Not of Standard Quality (NSQ) following failed quality control tests. The medications, sampled from various distribution and sales points across India, were manufactured by 17 pharmaceutical companies—some of which have business ties, subsidiaries, or product presence in Nigeria.
The companies named in the report include:
Abaris Healthcare Pvt Ltd
Alencure Biotech Pvt Ltd
Eurolife Healthcare Pvt Ltd
Health Biotech Ltd
HIGGS Healthcare
Karnataka Antibiotics & Pharmaceuticals Ltd (KAPL)
Laborate Pharmaceuticals India Ltd
Legend Industries
Martins & Brown Biosciences Pvt Ltd
Mascot Health Series Pvt Ltd
Micron Pharmaceutical
Orison Pharma International
Rivpra Formulation Pvt Ltd
Sai Parenterals Ltd
Symbiosis Pharmaceuticals Pvt Ltd
Syncom Formulations (India) Ltd
Zee Laboratories Ltd
In response, NAFDAC has called on healthcare professionals, pharmacists, and consumers across Nigeria to exercise heightened vigilance when handling pharmaceutical products, especially those of Indian origin.
Members of the public are urged to report suspected cases of substandard or falsified medicines to the nearest NAFDAC office, via the toll-free number 0800-162-3322, or by email at sf.alert@nafdac.gov.ng.
NAFDAC reaffirmed its commitment to protecting public health and disclosed that investigations are ongoing to determine the extent of the local distribution of the flagged products.
© 2022 TVC Communications - Owner of TVC News
© 2022 TVC Communications - Owner of TVC News